Clinical Trials /

CB-839 With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

NCT03528642

Description:

This phase 1b trial studies the side effects and best dose of glutaminase inhibitor CB-839 hydrochloride (CB-839) in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma. CB-839 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CB-839 with radiation therapy and temozolomide may work better than surgery, radiation therapy, and temozolomide in treating patients with IDH-mutated diffuse astrocytoma or anaplastic astrocytoma.

Related Conditions:
  • Anaplastic Astrocytoma
  • Diffuse Astrocytoma
Recruiting Status:

Recruiting

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: CB-839 With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
  • Official Title: A Phase 1b Trial of CB-839 in Combination With Radiation Therapy and Temozolomide in Patients With IDH-Mutated Diffuse Astrocytoma and Anaplastic Astrocytoma

Clinical Trial IDs

  • ORG STUDY ID: NCI-2018-00876
  • SECONDARY ID: NCI-2018-00876
  • SECONDARY ID: 10218
  • SECONDARY ID: 10218
  • SECONDARY ID: UM1CA186686
  • SECONDARY ID: UM1CA186709
  • NCT ID: NCT03528642

Conditions

  • Anaplastic Astrocytoma, IDH-Mutant
  • Diffuse Astrocytoma, IDH-Mutant

Interventions

DrugSynonymsArms
Telaglenastat HydrochlorideCB-839 HCl, Glutaminase Inhibitor CB-839 HydrochlorideTreatment (CB-839, temozolomide, RT)
TemozolomideCCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, TMZTreatment (CB-839, temozolomide, RT)

Purpose

This phase 1b trial studies the side effects and best dose of glutaminase inhibitor CB-839 hydrochloride (CB-839) in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma. CB-839 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving CB-839 with radiation therapy and temozolomide may work better than surgery, radiation therapy, and temozolomide in treating patients with IDH-mutated diffuse astrocytoma or anaplastic astrocytoma.

Detailed Description

      PRIMARY OBJECTIVE:

      I. Determine the maximum tolerated dose (MTD) and/or the recommended phase 2 dose (RP2D) of
      CB-839 hydrochloride (HCl) (telaglenastat) when combined with radiation therapy (RT) and
      temozolomide (TMZ) in patients with newly diagnosed IDH-mutated diffuse astrocytoma (DA) and
      anaplastic astrocytoma (AA).

      SECONDARY OBJECTIVES:

      I. To observe and record anti-tumor activity. II. Determine the safety and tolerability of
      RT/TMZ/CB-839 HCl (telaglenastat) in patients based on physician reported adverse event (AE)
      data.

      III. Estimate the 2-year progression-free survival (PFS2) of RT/TMZ/CB-839 HCl
      (telaglenastat) in patients with IDH-mutated glioma based on the Response Assessment in
      Neuro-Oncology (RANO) criteria.

      IV. Estimate the 2-year overall survival (OS2) of RT/TMZ/CB-839 HCl (telaglenastat) in
      patients with IDH-mutated glioma based on RANO criteria.

      CORRELATIVE OBJECTIVES:

      I. Determine the minor response rate (MRR) and clinical benefit rate (CBR) for the
      combination of CB-839 HCl (telaglenastat) and RT/TMZ in IDH-mutated glioma based on RANO
      criteria.

      II. Determine the patient-reported tolerability of RT/TMZ/CB-839 HCl (telaglenastat) using
      the MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) instrument to measure self-reported
      symptom severity and interference with daily activities.

      II. Determine the neurocognitive impact of CB-839 HCl (telaglenastat) when used in
      combination with RT/TMZ.

      III. Determine the effect of CB-839 HCl (telaglenastat)/RT/TMZ on plasma oncometabolite
      levels of glutamine, glutamate, aspartate, asparagine, and 2-hydroxyglutarate (2-HG) in
      patients with IDH-mutated glioma and associate the changes with disease response.

      IV. Determine the effect of CB-839 HCl (telaglenastat)/RT/TMZ on tumor glutamine and
      glutamate MRS signals in patients with IDH-mutated glioma and associate the signal with
      disease response.

      V. Determine the pharmacokinetics (PK) of CB-839 HCl (telaglenastat) when used alone and in
      combination with TMZ.

      VI. To perform molecular profiling assays on archived tumor tissue and peripheral blood,
      including, but not limited to, low-pass whole genome sequencing (WGS), whole exome sequencing
      (WES), and messenger RNA sequencing (RNA-Seq) in order to VIa. Identify potential predictive
      and prognostic biomarkers beyond any genomic alteration by which treatment may be assigned.

      VIb. Identify resistance mechanisms using genomic deoxyribonucleic acid (DNA)- and
      ribonucleic acid (RNA)-based assessment platforms.

      VII. To contribute genetic analysis data from de-identified biospecimens to Genomic Data
      Commons (GDC), a well annotated cancer molecular and clinical data repository, for current
      and future research; specimens will be annotated with key clinical data, including
      presentation, diagnosis, staging, summary treatment, and if possible, outcome.

      VIII. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA
      analysis), and nucleic acids obtained from patients at the Experimental Therapeutics Clinical
      Trials Network (ETCTN) Biorepository at Nationwide Children's Hospital.

      OUTLINE: This is a dose escalation study of CB-839.

      Patients receive CB-839 orally (PO) twice daily (BID) 7 days a week, temozolomide PO once
      daily (QD) 7 days a week, and undergo RT 5 days a week for up to 5.5 weeks (diffuse
      astrocytoma) or 6.5 weeks (anaplastic astrocytoma) in the absence of disease progression or
      unacceptable toxicity.

      After completion of study treatment, patients are followed up every 3 months for up to 2
      years.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (CB-839, temozolomide, RT)ExperimentalPatients receive CB-839 PO BID 7 days a week, temozolomide PO QD 7 days a week, and undergo RT 5 days a week for up to 5.5 weeks (diffuse astrocytoma) or 6.5 weeks (anaplastic astrocytoma) in the absence of disease progression or unacceptable toxicity.
  • Telaglenastat Hydrochloride
  • Temozolomide

Eligibility Criteria

        Inclusion Criteria:

          -  Patients must have histopathologic or molecular confirmation of either IDH-mutant DA
             or IDH-mutant AA. Acceptable IDH mutations for study eligibility include any IDH1
             mutation at codon 132 or any IDH2 mutation at codon 172.

          -  Age ≥16 years. The intended neurocognitive tests have not been validated in children
             below the age of 16.

          -  Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%).

          -  Hemoglobin > 9.0 g/dL

          -  Leukocytes >= 3.0 x 10^9/L

          -  Absolute neutrophil count >= 1.5 x 10^9/L

          -  Platelets >= 100 x 10^9/L

          -  International normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)

          -  Partial thromboplastin time (PTT) or activated partial thromboplastin time (APTT) =<
             1.5 x ULN

          -  Patients on a stable dose of anti-coagulation therapy will be allowed to participate
             if they have no signs of bleeding or clotting and the INR/PT and PTT/aPTT results are
             compatible with an acceptable risk-benefit ratio as per the investigator's discretion.

          -  Total bilirubin =< 1.5 x institutional ULN and < 3 mg/dL for patients with Gilbert's
             disease

          -  Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) &
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x
             institutional ULN

          -  Creatinine =< 1.5 x institutional ULN or creatinine clearance >= 60 mL/minute

          -  If there is history of human immunodeficiency virus (HIV) infection, patients must be
             on effective antiretroviral therapy and HIV viral load must be undetectable within 6
             months of study enrollment.

          -  If there is history of chronic hepatitis B virus (HBV) infection, patients must have
             either been treated or are on suppressive therapy (as indicated), and HBV viral load
             must be undetectable.

          -  If there is history of hepatitis C virus (HCV) infection, patients must have been
             treated and HCV viral load must be undetectable.

          -  Patient must have measurable disease by RANO criteria (dose expansion cohort only).

          -  Patient must be at least 7 days beyond stereotactic biopsy and/or at least 14 days
             beyond open craniotomy at the time of registration.

          -  Patients must have been on a stable or decreasing dose of corticosteroids over the
             last 7 days at the time of registration.

          -  Patients must have been on a stable or decreasing dose of antiepileptic therapy over
             the last 14 days at the time of registration.

          -  Females of childbearing potential must have a negative pregnancy test (=<14 days)
             prior to start of trial treatment. The effects of CB-839 HCl on the developing human
             fetus are unknown. For this reason and because alkylating agents as well as TMZ are
             known to be teratogenic, women of child-bearing potential and men must agree to use
             adequate contraception (hormonal or barrier method of birth control; abstinence) prior
             to study entry and for the duration of study participation. Should a woman become
             pregnant or suspect she is pregnant while she or her partner is participating in this
             study, she should inform her treating physician immediately. Men treated or enrolled
             on this protocol must also agree to use adequate contraception prior to the study, for
             the duration of study participation, and 4 months after completion of CB-839 HCl
             (telaglenastat) administration.

          -  Ability to understand and the willingness to sign a written informed consent document.

          -  Patients with a prior or concurrent malignancy whose natural history or treatment does
             not have the potential to interfere with the safety or efficacy assessment of the
             investigational regimen are eligible for this trial.

          -  Patients with known history or current symptoms of cardiac disease, or history of
             treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac
             function using the New York Heart Association functional classification. To be
             eligible for this trial, patients should be class 2B or better.

          -  Availability of archival FFPE tumor tissue collected within 12 months prior to
             registration.

        Exclusion Criteria:

          -  Patients must not have received prior chemotherapy to treat the glioma.

          -  Patients who are receiving any other investigational agents.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to CB-839 HCl (telaglenastat) or TMZ.

          -  Patient must not have received prior radiation therapy to the brain. Prior radiation
             therapy to the head and neck is also excluded if radiation fields overlap.

          -  No prior use of Gliadel wafers.

          -  Patient must have no evidence of either infratentorial or spinal involvement with
             tumor.

          -  Patients who are unable to swallow tablets.

          -  Patients who are at risk for impaired absorption of oral medication including, but not
             limited to, refractory vomiting, gastric resection/bypass, and duodenal/jejunal
             resection.

          -  Patients with uncontrolled intercurrent illness.

          -  Patients with a "currently active" second malignancy other than non-melanoma skin
             cancers. Patients are not considered to have a "currently active" malignancy if they
             have completed therapy and are free of disease for more than 3 years.

          -  Pregnant women are excluded from this study because CB-839 HCl (telaglenastat) is an
             agent with the potential for teratogenic or abortifacient effects. Because there is an
             unknown but potential risk for AEs in nursing infants secondary to treatment of the
             mother with CB-839 HCl (telaglenastat), breastfeeding should be discontinued if the
             mother is treated with CB-839 HCl (telaglenastat). These potential risks may also
             apply to TMZ.

          -  Adolescent patients who require sedation for magnetic resonance imaging (MRI) or
             magnetic resonance spectroscopy (MRS).

          -  Patients with psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  The primary language of communication for the patient must be English (dose expansion
             cohort only). The intended neurocognitive tests have not been validated in patients
             who do not primarily speak English.
      
Maximum Eligible Age:N/A
Minimum Eligible Age:16 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:Maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)
Time Frame:Up to 6.5 weeks
Safety Issue:
Description:MTD is defined as the dose level below the lowest dose that induces dose limiting toxicity (DLT) in at least 2 patients (out of 6). A total of 6 patients must be treated at the MTD. It is possible that the MTD will be unknown after this study (e.g., if the highest tested dose has fewer than 2 patients with DLT, out of 6). In this case, the highest dose is defined as the RP2D. A 3 + 3 cohort expansion design to determine toxicity-based dose escalation of glutaminase inhibitor CB-839 hydrochloride (CB-839 HCl) and external beam fractionated radiation therapy (RT) with concurrent temozolomide (TMZ) among patients with IDH-mutated diffuse astrocytoma (DA) or anaplastic astrocytoma (AA).

Secondary Outcome Measures

Measure:Objective response rate (ORR) as defined by Response Assessment in Neuro-Oncology (RANO) criteria
Time Frame:Up to 6 months from the start of study treatment
Safety Issue:
Description:ORR is defined as the rate of either complete response (CR), partial response (PR), or minor response (MR) by RANO criteria for low-grade gliomas at 6 months after initiation of RT/TMZ/CB-839 HCl therapy. The ORR will be estimated using properties of the binomial distribution. 95% exact confidence intervals will also be calculated.
Measure:Clinical benefit rate (CBR) as defined by RANO criteria
Time Frame:Up to 6 months from the start of study treatment
Safety Issue:
Description:CBR is defined as the rate of either CR, PR, MR, or stable disease (SD) by RANO criteria for low-grade gliomas at 6 months after initiation of RT/TMZ/CB-839 HCl therapy. The CBR will be estimated using properties of the binomial distribution. 95% exact confidence intervals will also be calculated.
Measure:Incidence of adverse events graded according to Common Terminology Criteria for Adverse Events (CTCAE)
Time Frame:Up to 2 years
Safety Issue:
Description:The safety and tolerability of RT/TMZ/CB-839 HCl in patients is based on physician reported adverse event (AE) data.
Measure:Progression-free survival (PFS2) as defined by response assessment in neuro-oncology (RANO) criteria
Time Frame:Up to 2 years
Safety Issue:
Description:PFS2 rate will be estimated using properties of the binomial distribution. 95% exact confidence intervals will also be calculated.
Measure:Overall survival (OS2) as defined by RANO criteria
Time Frame:Up to 2 years
Safety Issue:
Description:OS2 rate will be estimated using properties of the binomial distribution. 95% exact confidence intervals will also be calculated.
Measure:Assessment of pharmacokinetic (PK) parameters
Time Frame:Pre-dose, 0.5, 1, 2, 4, and 8 hours post-dose on days -7, 1, and 15
Safety Issue:
Description:The PK of CB-839 HCl will also be summarized using descriptive statistics and will be compared to historical data. Measurement of plasma concentrations of CB-839 HCl and its metabolites (if authentic standards are available) will be performed using validated liquid chromatography-tandem mass spectrometry (LC/MS/MS) assays. The plasma concentration-time data will be analyzed by standard noncompartmental analysis using the program Phoenix WinNonlin 6.4 to determine apparent total clearance of the drug from plasma after oral administration (Cl/F), area under the plasma concentration-time curve from time zero to time t (AUCt), area under the plasma concentration-time curve from time zero to infinity, Cmax, time to reach maximum plasma concentration following drug administration (Tmax), t1/2, and accumulation.
Measure:Assessment of self-reported symptoms as measured by MD Anderson Symptom Inventory-Brain Tumor (MDASI-BT) instrument
Time Frame:Up to 2 years
Safety Issue:
Description:MDASI-BT instrument is used to measure self-reported symptom severity and interference with daily activities. The study will use descriptive statistics to describe how patients rate symptom severity and interference with function at each time point. Compliance rates will be calculated as the number of received valid forms over the number of expected forms. Differences between groups in compliance will be tested by use of Fisher's exact test at every time point.
Measure:Assessment of neurocognitive impact
Time Frame:Baseline up to 2 years
Safety Issue:
Description:For each test in the battery, a standard error of measurement will be used to derive the Reliable Change Index (RCI) which will be used to represent the 90% confidence interval for the difference in raw scores from baseline to follow-up assessment will be coded as 1 (deterioration), 2 (no change), and 3 (improved) according to the RCI. Percentage of patients in each dose cohort who show meaningful losses or gains in the various tests or test domains over the course of the study will be provided by frequency tables. Dose cohort differences will be compared using chi-squared analysis. Time-to-progressions will be estimated by Kaplan-Meier method and analyzed by Cox regression model adjusting all stratification factors.
Measure:Assessment of plasma oncometabolites
Time Frame:Baseline up to day 71
Safety Issue:
Description:Plasma oncometabolites (asparagine, aspartate, glutamine, glutamate, and 2-HG) will be compared using changes in values after treatment with the patient's individual baseline values using either the paired t-test or the Mann-Whitney nonparametric U-test as needed. A significant change is defined as a 10% change from baseline.
Measure:Assessment of tumor oncometabolites as measured by magnetic resonance spectroscopy (MRS)
Time Frame:Baseline up to day 45
Safety Issue:
Description:Tumor oncometabolites (2-HG, glutamine, and glutamate, as measured by MRS) will be compared using changes in values after treatment with the patient's individual baseline values using either the paired t-test or the Mann-Whitney nonparametric U-test as needed. A significant change is defined as a 10% change from baseline.

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Recruiting
Lead Sponsor:National Cancer Institute (NCI)

Last Updated

September 17, 2020